Mycenax Biotech (4726) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.031x

Based on the latest financial reports, Mycenax Biotech (4726) has a cash flow conversion efficiency ratio of -0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-50.35 Million ≈ $-1.59 Million USD) by net assets (NT$1.64 Billion ≈ $51.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mycenax Biotech liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Mycenax Biotech - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Mycenax Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Mycenax Biotech Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mycenax Biotech ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Alumil Aluminium Industry S.A AT:ALMY	0.021x
Unison Co. Ltd KQ:018000	-0.080x
Ellsworth Convertible Growth & IF NYSE MKT:ECF	-0.076x
Tonghua Grape Wine Co Ltd SHG:600365	-0.411x
NX Filtration Holding BV AS:NXFIL	-0.009x
Hirequest Inc NASDAQ:HQI	0.097x
Seoul Broadcasting System KO:034120	0.025x
Chiang Mai Ram Medical Business Public Company Limited BK:CMR	-0.006x

Annual Cash Flow Conversion Efficiency for Mycenax Biotech (2017–2024)

The table below shows the annual cash flow conversion efficiency of Mycenax Biotech from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 4726 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$2.02 Billion ≈ $63.75 Million	NT$-191.68 Million ≈ $-6.04 Million	-0.095x	-76.72%
2023-12-31	NT$2.45 Billion ≈ $77.10 Million	NT$-131.18 Million ≈ $-4.13 Million	-0.054x	-10.84%
2022-12-31	NT$3.11 Billion ≈ $97.84 Million	NT$-150.19 Million ≈ $-4.73 Million	-0.048x	+36.95%
2021-12-31	NT$1.91 Billion ≈ $60.07 Million	NT$-146.23 Million ≈ $-4.61 Million	-0.077x	-153.36%
2020-12-31	NT$1.21 Billion ≈ $38.17 Million	NT$174.17 Million ≈ $5.49 Million	0.144x	+212.55%
2019-12-31	NT$1.10 Billion ≈ $34.72 Million	NT$-140.74 Million ≈ $-4.43 Million	-0.128x	+35.74%
2018-12-31	NT$907.01 Million ≈ $28.58 Million	NT$-180.27 Million ≈ $-5.68 Million	-0.199x	-399.11%
2017-12-31	NT$1.14 Billion ≈ $36.04 Million	NT$-45.55 Million ≈ $-1.44 Million	-0.040x	--

About Mycenax Biotech

TWO:4726 Taiwan Biotechnology

Market Cap

$162.63 Million

NT$5.16 Billion TWD

Market Cap Rank

#17445 Global

#900 in Taiwan

Share Price

NT$24.90

Change (1 day)

+1.22%

52-Week Range

NT$24.60 - NT$40.05

All Time High

NT$68.00